{
  "query": "Difference between pembrolizumab and nivolumab?",
  "response": "Both are PD-1 inhibitors with similar mechanisms. Key differences: pembrolizumab (approved 2014, dosing every 3 weeks) vs nivolumab (approved 2014, initially every 2 weeks). Efficacy is comparable in most indications, with subtle differences in side effect profiles.",
  "attention": {
    "sources": [
      "comparative-immunotherapy.pdf",
      "meta-analysis-PD1.pdf"
    ],
    "weights": [
      0.55,
      0.45
    ],
    "patterns": [
      "sources:2",
      "outcome:success"
    ]
  },
  "outcome": "success",
  "confidence": 0.88,
  "timestamp": 1760058208795,
  "memory_type": "long-term",
  "id": "57cb48b59df5c20af4bf853899ef44d6cfa9aae039039db787ac58ff2fd3d0f1"
}